A Study of SDI-118 in Participants in Remission From Depression

Summary

This is a multi-center, double-blind, randomized, placebo-controlled study to determine the safety, tolerability, and pharmacodynamics of SDI-118 in a once daily (QD) dosing regimen on male and female study participants reporting with cogntive decline and who in remission from depression.

Timeline

Start

2021-09-16

Primary completion

2022-03-11

Completion

2022-03-11

Outcome

Outcome not reported

Stopped: “Development Plan Amended”

Drugs

Indications